A Study of Obinutuzumab in Combination With High-Dose Methylprednisolone in Chronic Lymphocytic Leukemia Patients
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Dec 2018
Price : $35 *
At a glance
- Drugs Obinutuzumab (Primary) ; Methylprednisolone
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 19 Dec 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
- 26 Mar 2018 Status changed from recruiting to Active no longer recruiting.